LEXINGTON, MA, USA, October 21st, 2022 — CILcare, a leading R&D services company dedicated to ear disorders, announced today that the company, and its partner CBSET Inc., a not-for-profit translational research institute, have been recognized for their innovative preclinical auditory services in the third annual Hearing Technology Innovator Awards™. Through the annual awards program, Hearing […]
“Our study has documented, for the first time, the distributionof nerves and adjacent anatomies surrounding human hepatic arteries. This is the foundation for the development of catheter-based denervation technologies, providing invaluable guidance on the preferred treatment locations and depths in order to be effective,” said Dr. Rami Tzafriri, Director of Research & Innovation for CBSET […]
“Auditory research studies are typically performed using rodent models. Yet, owing to their size, implant studies often require a larger species with middle and inner ear anatomy more relevant to humans,” said Misty Williams-Fritze, DVM, MS, DACLAM, CBSET, co-lead researcher. Lexington, MA — February 19, 2021 — CBSET Inc., a not-for-profit translational research institute, announced […]
Montpellier, France — January 14th, 2021 — CILcare, the world-leading CRO specialized in the field of hearing, recently had the immense pleasure of welcoming Dr. Mathieu Schué to the team as Project Director of Drug Development & Translational Research. In this role, Mathieu Schué will dive into CILcare’s preclinical models and read-outs, validate reference compounds […]
Montpellier, France — November 9, 2020 — CBSET partner CILcare, a world leading CRO entirely dedicated to ear disorders, announced today the opening of a new subsidiary in Copenhagen, Denmark. Already established in the US, the French company is joining the Medicon Valley Alliance, a leading international life-sciences cluster in Northern Europe. This second subsidiary […]
“These preclinical studies transform our understanding of how drug coated balloons deliver drug to the artery and why there is no class effect, while also providing tools for understanding the role of tissue stiffening with disease. The combination of mechanistic insight with predictive modeling can help accelerate development of new technologies such as those including […]
LEXINGTON, MA — September 23, 2020 — CBSET Inc., a not-for-profit translational research institute, announced today that the company and its partner, CILcare, a leading CRO specializing in hearing disorders, have been nominated to receive a prestigious Prix Galien MedStartUp award for their collaboration in fighting hearing loss; the collaborators are nominated in the category […]
Montpellier, France, and Lexington, MA — September 3rd, 2020 — CILcare, world leading CRO specialized in the field of hearing, announced today that Dr. Marie-Pierre PASDELOU, CILcare’s co-founder and current Chief Development Officer, is taking over CILcare’s Regulatory Affairs and Quality Department as Chief Regulatory Officer. In parallel to offering CILcare’s sponsors strategic and operational […]
Montpellier, France, and Lexington, MA — June 15, 2020 — CILcare, world leading CRO entirely specialized in the field of hearing disorders, announces a strategic partnership with the start-up Vertidiag, a company specialized in balance disorders. By combining their unique know-how, CILcare and Vertidiag can propose a complete service offering to identify and develop therapeutic solutions […]
LEXINGTON, MA, May 19, 2020 — CBSET Inc., a not-for-profit translational research institute, announced today that its partner, CILcare, a leading CRO specializing in hearing disorders, has promoted Dr. Cyrille Sage to Director of CILcare’s U.S. operations. In his new role, Dr. Sage will be responsible for overseeing all operations performed at the joint CBSET-CILcare facility […]